Sarepta Therapeutics (SRPT.US) was first covered by Piper Sandler, which gave it an increase rating, and the target price was $157.00.
Sarepta Therapeutics(SRPT.US)获Piper Sandler首次覆盖，给予增持评级, 目标价157.00美元。
Sarepta Therapeutics (SRPT.US) was first covered by Piper Sandler, which gave it an increase rating, and the target price was $157.00.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.